

## Title (en)

Anti-tumour compounds containing quinazoline and tetrazole rings.

## Title (de)

Verbindungen, die Quinazoline und Tetrazolring enthalten, als Antitumorverbindungen.

## Title (fr)

Composés contenant des anneaux de quinazoline et tétrazole comme agents antitumorals.

## Publication

**EP 0562734 A1 19930929**

## Application

**EP 93301780 A 19930309**

## Priority

GB 9205320 A 19920311

## Abstract (en)

The invention relates to quinazoline derivatives, or pharmaceutically-acceptable salts thereof, which possess anti-tumour activity; to processes for their manufacture; and to pharmaceutical compositions containing them. The invention provides a quinazoline of the formula:- <CHEM> wherein R<1> is (1-4C)alkyl; the quinazoline ring may optionally bear one or two further substituents selected from halogeno, (1-4C)alkyl and (1-4C)alkoxy; R<2> is hydrogen or (1-4C)alkyl; R<3> includes hydrogen and (1-4C)alkyl; and Ar is optionally substituted phenylene or heterocyclene; or a pharmaceutically-acceptable salt or ester thereof.

## IPC 1-7

**A61K 31/495**; **C07D 403/12**; **C07D 403/14**

## IPC 8 full level

**A61K 31/505** (2006.01); **A61K 31/495** (2006.01); **A61K 31/517** (2006.01); **A61P 35/00** (2006.01); **C07D 239/88** (2006.01); **C07D 239/95** (2006.01); **C07D 257/04** (2006.01); **C07D 401/14** (2006.01); **C07D 403/12** (2006.01)

## CPC (source: EP KR US)

**A61K 31/41** (2013.01 - KR); **A61P 35/00** (2017.12 - EP); **C07D 401/14** (2013.01 - EP US); **C07D 403/12** (2013.01 - EP KR US); **Y02P 20/55** (2015.11 - EP US)

## Citation (search report)

- [X] EP 0373891 A2 19900620 - ICI PLC [GB], et al
- [X] EP 0459730 A2 19911204 - ICI PLC [GB], et al
- [YD] EP 0031237 A1 19810701 - NAT RES DEV [GB]
- [YD] EP 0204529 A2 19861210 - BRITISH TECH GROUP [GB]

## Cited by

US5804396A; US5837815A; US6103728A; US5837524A; US5747499A; US5789417A; US6818440B2; WO2005012260A3; US6342593B1; US7119174B2; WO9530673A1; WO03020300A1; US6861442B1; EP2311850A1; EP2332962A1; US6835546B1; US7354724B2; US6699861B1; US6495353B1; US6228641B1; US6844177B2; US7115710B2; EP2518083A2; US6716575B2; US6656716B1; US6680170B2; US6388063B1; US6207401B1

## Designated contracting state (EPC)

AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

## DOCDB simple family (publication)

**US 5955463 A 19990921**; AT E131823 T1 19960115; AU 3378293 A 19930916; AU 659277 B2 19950511; CA 2090942 A1 19930912; CA 2090942 C 20000208; CZ 281811 B6 19970212; CZ 36293 A3 19940119; DE 69301048 D1 19960201; DE 69301048 T2 19960515; DK 0562734 T3 19960506; EP 0562734 A1 19930929; EP 0562734 B1 19951220; ES 2081178 T3 19960216; FI 108793 B 20020328; FI 931067 A0 19930310; FI 931067 A 19930912; GB 2264946 A 19930915; GB 2264946 B 19950517; GB 9205320 D0 19920422; GB 9304807 D0 19930428; GR 3018501 T3 19960331; HK 21297 A 19970227; HU 211127 A9 19951030; IL 104984 A0 19930708; IL 104984 A 19980104; JP 3160111 B2 20010423; JP H06279438 A 19941004; KR 100221011 B1 19990915; KR 930019667 A 19931018; NO 301543 B1 19971110; NO 930881 D0 19930310; NO 930881 L 19930913; NZ 247122 A 19950726; RU 2111209 C1 19980520; TW 223635 B 19940511; ZA 931447 B 19930913

## DOCDB simple family (application)

**US 2815893 A 19930309**; AT 93301780 T 19930309; AU 3378293 A 19930225; CA 2090942 A 19930303; CZ 36293 A 19930308; DE 69301048 T 19930309; DK 93301780 T 19930309; EP 93301780 A 19930309; ES 93301780 T 19930309; FI 931067 A 19930310; GB 9205320 A 19920311; GB 9304807 A 19930309; GR 950403484 T 19951221; HK 21297 A 19970227; HU 9500202 P 19950614; IL 10498493 A 19930308; JP 5052593 A 19930311; KR 930003536 A 19930310; NO 930881 A 19930310; NZ 24712293 A 19930311; RU 93004793 A 19930310; TW 82101928 A 19930316; ZA 931447 A 19930301